查看文章

nih.gov 中的 [HTML]

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase …

作者

David Marin, Amr R Ibrahim, Claire Lucas, Gareth Gerrard, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, Dragana Milojkovic, Marco Bua, Jiri Pavlu, Christos Paliompeis, Alistair Reid, Katayoun Rezvani, John M Goldman, Letizia Foroni

发表日期

2012/1/1

期刊

Journal of Clinical Oncology

卷号

期号

页码范围

232

出版商

American Society of Clinical Oncology

简介

Purpose

We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.

引用总数

被引用次数：590

201120122013201420152016201720182019202020212022202320242 45 86 82 69 71 48 28 32 29 26 17 17 8

学术搜索中的文章

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang… - Journal of Clinical Oncology, 2012

被引用次数：590 相关文章所有 15 个版本